145 related articles for article (PubMed ID: 30140912)
1. Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.
Zic JA; Straka BT; McGirt LY; Nian H; Yu C; Brown NJ
JAMA Dermatol; 2018 Oct; 154(10):1221-1222. PubMed ID: 30140912
[TBL] [Abstract][Full Text] [Related]
2. Aprepitant as an antipruritic agent?
Duval A; Dubertret L
N Engl J Med; 2009 Oct; 361(14):1415-6. PubMed ID: 19797294
[No Abstract] [Full Text] [Related]
3. [Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma].
Palacios Zabalza I; López de Torre Querejazu A; Santos Ibañez A
Farm Hosp; 2014 Apr; 38(2):145-7. PubMed ID: 24669900
[TBL] [Abstract][Full Text] [Related]
4. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues.
Torres T; Fernandes I; Selores M; Alves R; Lima M
J Am Acad Dermatol; 2012 Jan; 66(1):e14-5. PubMed ID: 22177649
[No Abstract] [Full Text] [Related]
7. Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose.
Muñoz M; Parrilla J; Rosso M; Coveñas R
Acta Derm Venereol; 2019 May; 99(6):620-621. PubMed ID: 30734049
[No Abstract] [Full Text] [Related]
8. Aprepitant for the Treatment of Chronic Refractory Pruritus.
He A; Alhariri JM; Sweren RJ; Kwatra MM; Kwatra SG
Biomed Res Int; 2017; 2017():4790810. PubMed ID: 29057261
[TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case report.
Villafranca JJ; Siles MG; Casanova M; Goitia BT; Domínguez AR
J Med Case Rep; 2014 Sep; 8():300. PubMed ID: 25200537
[TBL] [Abstract][Full Text] [Related]
10. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat.
Meyer N; Paul C; Misery L
Acta Derm Venereol; 2010; 90(1):12-7. PubMed ID: 20107719
[TBL] [Abstract][Full Text] [Related]
11. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma.
Demierre MF; Taverna J
J Am Acad Dermatol; 2006 Sep; 55(3):543-4. PubMed ID: 16908377
[No Abstract] [Full Text] [Related]
12. Aprepitant for refractory nivolumab-induced pruritus.
Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
[TBL] [Abstract][Full Text] [Related]
13. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant in refractory pruritus of systemic lymphoproliferative disorders.
Pulido-Perez A; Carretero-Lopez F; Bergon-Sendin M; Nieto-Benito LM; Romero-Jimenez R; Dorado-Herrero N; Bastos-Oreiro MB; Suárez-Fernández R
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e422-e424. PubMed ID: 32180276
[No Abstract] [Full Text] [Related]
15. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Santini D; Vincenzi B; Guida FM; Imperatori M; Schiavon G; Venditti O; Frezza AM; Berti P; Tonini G
Lancet Oncol; 2012 Oct; 13(10):1020-4. PubMed ID: 22995650
[TBL] [Abstract][Full Text] [Related]
16. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY
J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma.
Borja-Consigliere HA; López-Pestaña A; Vidal-Manceñido MJ; Tuneu-Valls A
Actas Dermosifiliogr; 2014 Sep; 105(7):716-8. PubMed ID: 24139470
[No Abstract] [Full Text] [Related]
19. [A patient with erythroderma and pruritus: Sézary syndrome].
Overweel AFP; Langerak AW; Damman J; de Haas ELM; Weerkamp F; Sandberg Y
Ned Tijdschr Geneeskd; 2022 Feb; 166():. PubMed ID: 35499588
[TBL] [Abstract][Full Text] [Related]
20. Emerging Treatments and Novel Pathways in Pruritus.
Besner Morin C; Misery L
J Cutan Med Surg; 2019; 23(5):528-536. PubMed ID: 31167547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
